About 10X Genomics Inc
Ticker
info
TXG
Trading on
info
NASDAQ
ISIN
info
US88025U1097
Industry
info
Health Information Services
Sector
info
Healthcare
CEO
info
Dr. Serge Saxonov Ph.D.
Headquarters
info
6230 Stoneridge Mall Road, Pleasanton, CA, United States, 94588-3260
Employees
info
1,306
Website
info
10xgenomics.com
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Metrics
BasicAdvanced
Market cap
info
$1.04B
P/E ratio
info
-
EPS
info
-$1.52
Dividend Yield
info
0.00%
Beta
info
2.01
Forward P/E ratio
info
196.08
EBIDTA
info
$-157M
Ex dividend date
info
-
Price & volume
Market cap
info
$1.04B
Average daily volume
info
4M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
196.08
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
1.71
Price to book
info
1.47
Earnings
EPS
info
-$1.52
EPS estimate (current quarter)
info
-$0.11
EPS estimate (next quarter)
info
-$0.19
EBITDA
info
$-157M
Revenues (TTM)
info
$611M
Revenues per share (TTM)
info
$5.07
Technicals
Beta
info
2.01
52-week High
info
$28.25
52-week Low
info
$6.78
50-day moving average
info
$9.58
200-day moving average
info
$15.53
Short ratio
info
3.91
Short %
info
17.73%
Management effectiveness
ROE (TTM)
info
25.17%
ROA (TTM)
info
12.77%
Profit margin
info
29.90%
Gross profit margin
info
$415M
Operating margin
info
30.20%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
10.30%
Share stats
Outstanding Shares
info
109M
Float
info
107M
Insiders %
info
1.90%
Institutions %
info
100.36%
Analyst Insights & forecasts
info

48% Buy

47% Hold

5% Sell

Based on information from 17 analysts.

Average price target

info
$15.27
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.50
-$0.50
-
Q1 • 24Beat
-$0.32
-$0.48
33.33%
Q2 • 24Beat
-$0.30
-$0.34
11.76%
Q3 • 24Beat
-$0.14
-$0.11
27.09%
Q4 • 24Beat
-
-
-
Q1 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$152M
$-35.8M
23.58%
Q3 • 24
$165M
$-49M
29.71%
Q4 • 24
8.81%
37.13%
26.02%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$938M
$215M
22.93%
Q3 • 24
$919M
$209M
22.70%
Q4 • 24
2.04%
3.02%
1.00%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$21.6M
$-3.6M
$0.2M
$17.8M
Q3 • 24
$-6.7M
$-51.6M
$4.5M
$-9.5M
Q4 • 24
131.18%
1,325.98%
2,795.51%
153.31%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a 10X Genomics Inc share?
Collapse

10X Genomics Inc shares are currently traded for undefined per share.

How many shares does 10X Genomics Inc have?
Collapse

10X Genomics Inc currently has 109M shares.

Does 10X Genomics Inc pay dividends?
Collapse

No, 10X Genomics Inc doesn't pay dividends.

What is 10X Genomics Inc 52 week high?
Collapse

10X Genomics Inc 52 week high is $28.25.

What is 10X Genomics Inc 52 week low?
Collapse

10X Genomics Inc 52 week low is $6.78.

What is the 200-day moving average of 10X Genomics Inc?
Collapse

10X Genomics Inc 200-day moving average is $15.53.

Who is 10X Genomics Inc CEO?
Collapse

The CEO of 10X Genomics Inc is Dr. Serge Saxonov Ph.D..

How many employees 10X Genomics Inc has?
Collapse

10X Genomics Inc has 1,306 employees.

What is the market cap of 10X Genomics Inc?
Collapse

The market cap of 10X Genomics Inc is $1.04B.

What is the P/E of 10X Genomics Inc?
Collapse

The current P/E of 10X Genomics Inc is null.

What is the EPS of 10X Genomics Inc?
Collapse

The EPS of 10X Genomics Inc is -$1.52.

What is the PEG Ratio of 10X Genomics Inc?
Collapse

The PEG Ratio of 10X Genomics Inc is null.

What do analysts say about 10X Genomics Inc?
Collapse

According to the analysts 10X Genomics Inc is considered a buy.